Enhanced glioblastoma selectivity of harmine via the albumin carrier. - GreenMedInfo Summary
Enhanced Glioblastoma Selectivity of Harmine via the Albumin Carrier.
J Biomed Nanotechnol. 2022 Apr 1 ;18(4):1052-1063. PMID: 35854453
Shi-Hui Liu
Glioblastoma, the most common tumor in the brain, has witnessed very little clinical progress over the last decades. Exploring and discovering new therapeutic strategies for glioblastoma has become a critical problem. Harmine (HM), belonging to the beta-carboline alkaloid, is a natural product and isolated from the seeds ofL., which own notable antitumor activity. However, the poor water solubility and less selectivity of HM severely limit its clinical use. For enhancing its selective ability to tumor cells, we fabricated a kind of protein nanoparticles (BSA-HM NPs), composed of the modified bovine serum albumin (BSA) and HM. It was substantiated throughandexperiment that BSA-HM NPs could predominantly accumulate in tumor tissues and exhibited remarkably enhanced antitumor efficacy. This study provides a promising strategy to improve the bioavailability and avoid side effects of HM as antitumor agents by choosing BSA as carriers.